OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
OmniAb, Inc. (
NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9th with investors registered for the event.
OmniAb Announces $30 Million Private Placement
OmniAb, Inc. (
NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expenses. The net proceeds from the financing are expected to be used by OmniAb for general corporate purposes. The private placement is expected to close on or about August 26, 2025, subject to customary closing conditions.
OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. (
NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates.
OmniAb to Report Second Quarter 2025 Financial Results on August 6
OmniAb, Inc. (
NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Wednesday, August 6, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit
OmniAb, Inc. (
NASDAQ: OABI) today announced its participation in the 21st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial intelligence (AI), in a presentation by Bob Chen, Ph.D., Vice President, Discovery Systems, titled “xPloration: Simplifying Deep Antibody Mining for Maximum Impact.”
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. (
NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates.
OmniAb Introduces the xPloration® Partner Access Program
OmniAb, Inc. (
NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
OmniAb to Participate in Five Upcoming Investor Conferences
OmniAb, Inc. (
NASDAQ: OABI) today announced that management will be participating in five investor conferences over the coming weeks.
OmniAb Announces Two New Appointments to its Board of Directors
OmniAb, Inc. (
NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb’s partnership base. These Board changes are effective immediately and increase the number of Directors to seven.
OmniAb to Report First Quarter 2025 Financial Results on May 8
OmniAb, Inc. (
NASDAQ: OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
OmniAb, Inc. (
NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates.
OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
OmniAb, Inc. (
NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb to Participate in Two Investor Conferences in March
OmniAb, Inc. (
NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March.
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb, Inc. (
NASDAQ: OABI) today announced that two presentations featuring the Company’s technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego.
OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
OmniAb, Inc. (
NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates.
OmniAb to Participate in Two Investor Conferences in November
OmniAb, Inc. (
NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of November.
